Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/793
Title: Programmed cell death-1 inhibition in lymphoma.
Authors: Hawkes, Eliza A.
Grigg, Andrew
Chong, Geoff
Issue Date: 2015
Publisher: Elsevier
Place of publication: Philadelphia, PA
Publication Title: The Lancet Oncology
Volume: 16
Start Page: e234
End Page: e245
Abstract: Cancers can evade the host immune system by inducing upregulation of immune inhibitory signals. Anti-programmed cell death-1 (PD-1) monoclonal antibodies block these inhibitory signals allowing the host to mount an immune response against malignant cells. This class of drugs is active in solid tumours, where upregulation of cell-surface PD-1 ligand proteins is nearly uniform. Because lymphoma is a malignancy of immune system cells, the role of the PD-1 pathway in these neoplasms is more complex. However, early clinical trials using PD-1 inhibitors have shown significant clinical activity in various subtypes of relapsed lymphoma. In this Review, we assess the scientific literature on the role of the PD-1 pathway in lymphoma, the relevant clinical data for PD-1 inhibition, and future strategies for this next generation of anticancer agents.
URI: http://hdl.handle.net/11054/793
Resource Link: http://www.sciencedirect.com/science/article/pii/S1470204515701038
ISSN: 1470-2045
Internal ID Number: 00777
Health Subject: CELL DEATH
IMMUNE SYSTEM
LYMPHOMA
NEOPLASMS
PROGRAMMED CELL DEATH 1 RECEPTOR
Type: Journal Article
Article
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.